FISH assessment is done by averaging the HER2 gene copy number and the HER2/CEP17 ratio of 20 to over 100 nuclei of invasive cancer cells, though intra-tumoral genetic heterogeneity is a well-known phenomenon and a challenge for HER2 evaluation in some breast cancer cases23. The gene discussed is ERBB2; the disease is breast carcinoma.